Cisplatin as single-agent chemotherapy in patients with liver dysfunction due to metastases

Onkologie

Volumn 32, Issue 7, 2009, Pages 400-404

  Wilop, Stefan ^a   Dada, Reyad ^a   Galm, Oliver ^a   Jousten, Peter ^b   Osieka, Rainhardt ^a   Jost, Edgar ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b St Nikolaus Hospital   (Belgium)

Author keywords

Chemotherapy; Cisplatin; Liver failure; Solid tumour

Indexed keywords

BILIRUBIN; CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; FLUOROURACIL; IRINOTECAN; MERCAPTOPURINE; OXALIPLATIN; PLATINUM COMPLEX; VINBLASTINE;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; BREAST TUMOR; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG TOLERANCE; FEMALE; HUMAN; LEUKOPENIA; LIVER DYSFUNCTION; LIVER FUNCTION; LUNG TUMOR; MALE; MALIGNANT HISTIOCYTOSIS; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; PAROTID GLAND TUMOR; PRIMARY TUMOR; PROGNOSIS; SOLID TUMOR; STOMACH TUMOR; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CISPLATIN; FEMALE; HUMANS; LIVER FAILURE; LIVER NEOPLASMS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 68149150649     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000218353     Document Type: Article

References (25)

1. Alexopoulou A, Koskinas J, Deutsch M, Delladetsima J, Kountouras D, Dourakis SP: Acute liver failure as the initial manifestation of hepatic infiltration by a solid tumor: report of 5 cases and review of the literature. Tumori 2006;92:354-357.
2. Geller DA, Tsung A, Marsh JW, Dvorchik I, Gamblin TC, Carr BI: Outcome of 1000 liver cancer patients evaluated at the UPMC Liver Cancer Center. J Gastrointest Surg 2006;10:63-68.
3. Zinser JW, Hortobagyi GN, Buzdar AU, Smith TL, Fraschini G: Clinical course of breast cancer patients with liver metastases. J Clin Oncol 1987;5:773-782.
4. Eklund JW, Trifilio S, Mulcahy MF: Chemotherapy dosing in the setting of liver dysfunction. Oncology (Williston Park) 2005;19:1057-1063; discussion 1063-1054,1069.
5. Koren G, Beatty K, Seto A, Einarson TR, Lishner M: The effects of impaired liver function on the elimination of antineoplastic agents. Ann Pharmacother 1992;26:363-371.
6. Fakih MG: 5-Fluorouracil, leucovorin and oxaliplatin (FOLFOX) in the treatment of metastatic colon cancer with severe liver dysfunction. Oncology 2004; 67:222-224.
7. Sharma RA, Decatris MP, Santhanam S, Roy R, Osman AE, Clarke CB, Khanna S, O'Byrne KJ: Reversibility of liver failure secondary to metastatic breast cancer by vinorelbine and cisplatin chemotherapy. Cancer Chemother Pharmacol 2003;52: 367-370.
8. Honecker FU, Brummendorf TH, Klein O, Bokemeyer C: Safe use of oxaliplatin in a patient with metastatic breast cancer and combined renal and hepatic failure. Onkologie 2006;29:273-275.
9. Rajeswaran A, Trojan A, Burnand B, Giannelli M: Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials. Lung Cancer 2008;
10. Flechon A, Rivoire M, Droz JP: Management of advanced germ-cell tumors of the testis. Nat Clin Pract Urol 2008;5:262-276.
11. Ohtsu A: Chemotherapy for metastatic gastric cancer: past, present, and future. J Gastroenterol 2008; 43:256-264.
12. Ott I, Gust R: Preclinical and clinical studies on the use of platinum complexes for breast cancer treatment. Anticancer Agents Med Chem 2007;7:95-110.
13. Sirohi B, Arnedos M, Popat S, Ashley S, Nerurkar A, Walsh G, Johnston S, Smith IE: Platinum-based chemotherapy in triple-negative breast cancer. Ann Oncol 2008;19:1847-1852.
14. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
15. Vauthey JN, Pawlik TM, Ribero D, Wu TT, Zorzi D, Hoff PM, Xiong HQ, Eng C, Lauwers GY, Mino-Kenudson M, Risio M, Muratore A, Capussotti L, Curley SA, Abdalla EK: Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006;24:2065-2072.
16. Schull B, Scheithauer W, Kornek GV: Capecitabine as salvage therapy for a breast cancer patient with extensive liver metastases and associated impairment of liver function. Onkologie 2003;26:578-580.
17. Twelves C, Glynne-Jones R, Cassidy J, Schuller J, Goggin T, Roos B, Banken L, Utoh M, Weidekamm E, Reigner B: Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. Clin Cancer Res 1999; 5:1696-1702.
18. Hwang SJ, Park JW, Lee SD, Kim GJ, Sin CH, Nam SH, Kim BS: Capecitabine and oxaliplatin (XELOX) for the treatment of patients with metastatic gastric cancer and severe liver dysfunction. Korean J Intern Med 2006;21:252-255.
19. Martoni AA, Bernardi A, Quercia S: Trastuzumab plus estrogen suppression as salvage treatment in a case of liver failure due to metastatic breast cancer. Anticancer Res 2006;26:3739-3744.
20. Moosmann N, Laessig D, Michaely HJ, Schulz C, Heinemann V: Effective second-line treatment with cetuximab and bevacizumab in a patient with hepatic metastases of colorectal cancer and hyperbilirubinemia. Onkologie 2007;30:509-512.
21. Srinivasan S, Parsa V, Liu CY, Fontana JA: Trastuzumab-induced hepatotoxicity. Ann Pharmacother 2008;42:1497-1501.
22. Kong JH, Yoo SH, Lee KE, Nam SH, Kwon JM, Lee SM, Chang HJ, Choi MY, Cho MS, Mun YC, Nam E, Lee SN, Seong CM: Early imatinibmesylate-induced hepatotoxicity in chronic myelogenous leukaemia. Acta Haematol 2007;118:205-208.
23. Liu W, Makrauer FL, Qamar AA, Janne PA, Odze RD: Fulminant hepatic failure secondary to erlotinib. Clin Gastroenterol Hepatol 2007;5:917-920.
24. Miller AA, Murry DJ, Owzar K, Hollis DR, Lewis LD, Kindler HL, Marshall JL, Villalona-Calero MA, Edelman MJ, Hohl RJ, Lichtman SM, Ratain MJ: Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101. J Clin Oncol 2007;25: 3055-3060.
25. Erlotinib Linked to Deaths in Patients With Hepatic Impairment, Advanced Solid Tumours. Doctor's Guide 2008;December 17th, www.docguide.com.